Envista Holdings Corporation (NYSE:NVST) Stock Has Average Price Target of $28.86

Envista Holdings Corporation (NYSE:NVST) has been given a consensus rating of “Hold” by the seventeen analysts that are presently covering the company, Marketbeat.com reports. Eleven research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $29.00.

A number of analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft set a $32.00 price objective on shares of Envista in a research note on Thursday, September 3rd. BMO Capital Markets cut their price objective on shares of Envista from $29.00 to $26.00 and set a “market perform” rating on the stock in a report on Monday, September 28th. UBS Group upped their price objective on shares of Envista from $27.00 to $29.00 and gave the company a “neutral” rating in a research report on Thursday. Leerink Partners lowered their target price on Envista from $35.00 to $32.00 and set an “outperform” rating for the company in a research note on Wednesday, October 14th. Finally, Robert W. Baird lowered Envista from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $34.00 to $26.00 in a research report on Thursday, October 15th.

Trending Headlines about Envista

Here are the key news stories impacting Envista this week:

• Positive Sentiment: Q3 results topped expectations: Envista reported adjusted earnings of $0.40 per share and revenue of $691.5 million, both above analyst estimates. Revenue rose 3.2% year over year, while earnings increased from $0.32 a year earlier. Envista tops Q3 earnings and revenue estimates
• Positive Sentiment: 2026 outlook raised: Management lifted its earnings outlook, citing pricing and productivity gains—an encouraging signal for near-term profitability. Q3 earnings-call highlights
• Positive Sentiment: UBS raised its price target from $27 to $29, though it maintained a Neutral rating. UBS Group stock recommendations
• Neutral Sentiment: Some valuation commentary argues NVST may be undervalued following a substantial prior decline, while a Zacks article highlights its momentum score. These are analyst perspectives rather than new company developments. Envista could be undervalued on earnings guidance
• Negative Sentiment: China remains a forward-looking risk: Procurement reforms there could weigh on margins as Envista enters 2027, potentially offsetting some benefits from pricing and productivity improvements. Q3 earnings-call highlights

Insider Buying and Selling

In other Envista news, SVP Mischa Reis sold 8,000 shares of Envista stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $27.50, for a total value of $220,000.00. Following the completion of the transaction, the senior vice president owned 27,321 shares of the company’s stock, valued at $751,327.50. The trade was a 22.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.99% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Envista

Several large investors have recently made changes to their positions in the company. Diversified Trust Co acquired a new position in Envista during the third quarter valued at $755,000. AlphaCore Capital LLC purchased a new position in Envista during the 3rd quarter valued at about $330,000. Hohimer Wealth Management LLC boosted its holdings in shares of Envista by 6.3% during the third quarter. Hohimer Wealth Management LLC now owns 10,934 shares of the company’s stock worth $257,000 after purchasing an additional 651 shares during the period. Brighton Jones LLC boosted its holdings in shares of Envista by 36.0% during the third quarter. Brighton Jones LLC now owns 20,908 shares of the company’s stock worth $491,000 after purchasing an additional 5,540 shares during the period. Finally, CenterBook Partners LP grew its position in Envista by 2.2% during the third quarter. CenterBook Partners LP now owns 26,441 shares of the company’s stock valued at $621,000 after purchasing an additional 581 shares in the last quarter.

Envista Price Performance

NVST stock opened at $25.20 on Thursday. The firm has a 50 day moving average of $24.38 and a 200-day moving average of $25.74. The company has a market cap of $4.05 billion, a price-to-earnings ratio of 6.51, a PEG ratio of 1.27 and a beta of 0.94. The company has a current ratio of 2.45, a quick ratio of 2.07 and a debt-to-equity ratio of 0.46. Envista has a 12-month low of $18.77 and a 12-month high of $30.42.

Envista (NYSE:NVST) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.36 by $0.04. The company had revenue of $691.50 million for the quarter, compared to the consensus estimate of $688.74 million. Envista had a net margin of 22.01% and a return on equity of 8.26%. The company’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.32 earnings per share. As a group, equities analysts expect that Envista will post 1.56 EPS for the current fiscal year.

About Envista

Envista Holdings Corporation (NYSE: NVST) is a global dental products and technologies company headquartered in Brea, California. The company develops, manufactures and markets products used by dentists, dental specialists, dental laboratories and other oral health professionals.

Envista’s portfolio includes dental implants, orthodontic systems, digital imaging and workflow solutions, dental consumables, treatment equipment and related technologies. Its brands include Nobel Biocare, Ormco, DEXIS and Kerr, which provide products and services spanning implant dentistry, orthodontics, diagnostic imaging, restorative care and general dental practice management.

Envista was established as an independent public company in 2019 following its separation from Danaher Corporation.